Endlyz UK Ltd
Research and experimental development on biotechnology · London
ActiveUnited KingdomIncorporated 2021Private Limited Company
Financial position
Accounts to 2026-03-31 · GBP · Company accounts
Net assets
−£351,214
Cash
£224,222
Turnover
—
Profit / loss
—
Current assets
£971,296
Creditors < 1 year
£1,342,634
Equity
−£351,214
Average employees
5
Balance-sheet trend
GBP · companyFinancial statements
Selected figures from the best-ranked available filing for each period. Missing values remain unknown.
Some figures were read by AI from scanned accounts, so small errors are possible. View the filed accounts
| Reported figures | 2026-03-31Company · AI-read | 2025-03-31Company · AI-read |
|---|---|---|
| Balance sheet | ||
| Net assets | −£351,214 | £921,218 |
| Equity | −£351,214 | £921,218 |
| Share capital | £1,324 | £1,139 |
| Retained earnings | −£12,589,659 | −£9,467,227 |
| Assets | ||
| Fixed assets | £20,124 | — |
| Intangible assets | £20,124 | — |
| Current assets | £971,296 | £2,523,674 |
| Cash at bank | £224,222 | £918,527 |
| Debtors | £747,074 | £1,605,147 |
| Liabilities | ||
| Creditors within one year | £1,342,634 | £1,602,456 |
| Bank loans & overdrafts | £150,120 | — |
| Net current assets | −£371,338 | £921,218 |
| Assets less current liabilities | −£351,214 | £921,218 |
| Operating costs | ||
| Amortisation | £4,008 | — |
| People & pay | ||
| Average employees | 5 | 5 |
| Pension costs | £112,131 | £45,919 |
| Source evidence | View filing | View filing |
From the accounts
What the accounts for 2026-03-31 say about themselves, read by AI from the scanned filing.
- Auditor
- PEM Audit Limited · senior statutory auditor Roberta Newman
- Audit opinion
- Clean (unmodified)
- Immediate parent
- EndLyz Therapeutics, Inc. · United States
- Ultimate parent
- EndLyz Therapeutics, Inc. · United States
- Accounts
- Small company · FRS 102 Section 1A
- Approved
- 2026-07-23, signed by Joanna Wolak
Related parties (4)
- SV Health Managers LLP · services recharged · £25,843
- SV Health Managers LLP · services recharged · £29,836
- SV Health Managers LLP · amount owed to SV Health Managers LLP · £Nil
- SV Health Managers LLP · amount owed to SV Health Managers LLP · £1,384
Borrowings (1)
- Other loans; unsecured, drawn down on 26 March 2026 and repaid on 2 April 2026 · 150,120 · 8% per annum · Repayable on the closing of investment in EndLyz Therapeutics, Inc.; repaid on 2 April 2026 · secured on Unsecured
Shares issued in the year (1)
- 1,850,000 Ordinary · for £1,850,000 · 2026-03-26
Share classes (2)
- 13,238,345 Ordinary of £0.0001
- 11,388,345 Ordinary of £0.0001
Events after the year end (1)
- Subsequent to the year end, the Company amended its research project with the University of Oxford providing for it to run to 31 March 2027. Under the terms of the amended agreement the Company has a contractual commitment to provide a financial contribution of £695,504 with payments due in April 2026, August 2026, October 2026 and January 2027.
Secured borrowing
Registered charges, lenders and security interests.
Charges and related records
1 outstanding chargesFixed · created 2025-12-01
—
Outstanding